ESH Video

John Goldman Award




The European School of Haematology (ESH) is proud to present the John Goldman Award.

The recipient of this annual award will receive a total of 80K€ to finance or co-finance a research project with a focus on disease control related research in haematological malignancies: Treatment Free Remission, Minimal Residual Disease and other biomarkers of long-term remission or cure.

The research project will have a maximum duration of two years.

Submitted projects must:

  • aim  to develop a method, algorithm or test to reliably identify patients able to benefit from long-term remission or cure, including in the context of treatment discontinuation,
  • demonstrate potential, based on solid scientific evidence, to improve healthcare standards for patients suffering from hematological malignancies.

–>The Call for Applications for the 3rd John Goldman Award will open on November 20th, 2020.
The deadline for Submission is March 1st, 2021.
All submitted applications will be peer reviewed independently by committee of academic researchers appointed by ESH.


For further information please contact with copy to

European School of Haematology (ESH)
Saint-Louis Research Institute,
Saint-Louis Hospital,
1 avenue Claude Vellefaux
Paris 75010, France





Dr. Vaidehi Krishnan

Laboratory of Hematological Malignancies, DUKE-NUS, Singapore

For her two year project on
“High dimensional single cell analysis to 
predict TFR at the time of CML diagnosis”

“I am honoured and thankful to be chosen as the recipient of the John Goldman Research Award this year.  Our project aims to interrogate diagnostic CML bone marrow samples using the latest single-cell approaches, and identify patients who will have durable treatment free responses. By integrating the results of our analyses with established clinical workflows, we hope to develop a test that can reliably predict the outcome of TKI discontinuation.  This prestigious award from the European School of Haematology offers us the opportunity to leverage cutting-edge technologies toward our long-term goal of developing curative approaches for patients with CML.” 





Dr. Ilaria Pagani

Leukaemia Research Group, Cancer Program, SAHMRI, Adelaide, Australia

For her two year project on
“Use of machine learning to integrate clinical data and biomarkers to optimise prediction of TFR”

“It is an honour and a pleasure to be the first John Goldman Research Prize Awardee. Receiving funding support from the European School of Haematology (ESH) is a privilege. It represents a critical step in my career towards becoming an independent investigator and provides the opportunity to build new collaborations. My project aims to identify bioassays that can be integrated with clinical data in a machine learning system to develop a personalized predictive model for treatment free remission (TFR). I expect it will bring novel insights into the biology of TFR, opening new horizons toward the discovery of targeted therapies and improving TFR patient outcome.” 


We invite you to watch the panel discussion video on the 1st International John Goldman Research Award on Treatment Free Remission, with:
– Hervé Dombret, ESH President, Saint-Louis Research Institute, Saint-Louis Hospital, Paris (Moderator),
– Daniela Krause, ESH Scientific Committee member, Georg-Speyer-Haus and Goethe University Frankfurt (Panelist),
– François-Xavier Mahon, ESH Scientific Committee past member, Institut Bergonié, Bordeaux (Panelist),
– Ilaria Pagani, 1st John Goldman Awardee, South Australian Health and Medical Research Institute, Adelaide (Panelist),
– Ana Rita Ferreira, Medical Director CML, Novartis Europe (Panelist):



ESH extends sincere thanks to the 2019 and 2020 Award reviewers:

Jorge Cortes (Augusta, USA)
Michael Hallek (Cologne, Germany)
Hervé Dombret (Paris, France)
Andreas Hochhaus (Jena, Germany)
Alessandro Vannucchi (Florence, Italy)
Andrew Rawstron (Leeds, UK)